Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$1.03 USD
+0.08 (7.85%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.04 +0.01 (0.97%) 6:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Applied DNA Sciences Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 13 | 18 | 9 | 2 | 5 |
Cost Of Goods | 8 | 13 | 4 | 1 | 1 |
Gross Profit | 6 | 5 | 5 | 1 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 19 | 18 | 14 | 14 |
Income After Depreciation & Amortization | -11 | -14 | -13 | -13 | -9 |
Non-Operating Income | 1 | 6 | -1 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -8 | -14 | -13 | -9 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -8 | -14 | -13 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -8 | -14 | -13 | -9 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -10 | -13 | -12 | -12 | -9 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -11 | -14 | -13 | -13 | -9 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 0.65 | 0.45 | 0.35 | 0.20 | 0.05 |
Diluted EPS Before Non-Recurring Items | -15.20 | -23.60 | -36.40 | -66.40 | -209.20 |
Diluted Net EPS (GAAP) | -15.20 | -18.60 | -41.40 | -66.40 | -193.80 |
Fiscal Year end for Applied DNA Sciences Inc falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.80 | 0.93 | 0.89 | 0.78 | 2.92 |
Cost Of Goods | 0.55 | 0.63 | 0.66 | 0.70 | 1.65 |
Gross Profit | 0.25 | 0.30 | 0.23 | 0.08 | 1.27 |
SG&A, R&D, and Dept/Amort Expenses | 3.59 | 3.91 | 4.02 | 4.25 | 4.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.34 | -3.61 | -3.79 | -4.17 | -2.86 |
Non-Operating Income | 5.20 | -0.88 | 2.66 | 0.56 | -0.26 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 1.85 | -4.49 | -1.13 | -3.62 | -3.11 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | -0.03 | -0.02 | -0.03 | -0.03 | -0.01 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 1.85 | -4.49 | -1.13 | -3.62 | -3.11 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 1.88 | -4.47 | -1.11 | -3.59 | -3.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.01 | 0.87 | 0.68 | 0.68 | 0.65 |
Diluted EPS Before Non-Recurring Items | 0.47 | -5.31 | -1.80 | -5.20 | -4.80 |
Diluted Net EPS (GAAP) | 0.47 | -5.31 | -1.80 | -5.40 | -4.80 |